These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16875829)

  • 1. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
    Nar H; Werle K; Bauer MM; Dollinger H; Jung B
    J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
    Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
    Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
    Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
    J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
    [No Abstract]   [Full Text] [Related]  

  • 10. Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.
    Zapico JM; Serra P; García-Sanmartín J; Filipiak K; Carbajo RJ; Schott AK; Pineda-Lucena A; Martínez A; Martín-Santamaría S; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2011 Jun; 9(12):4587-99. PubMed ID: 21552627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M; Tordai H; Trexler M; Bányai L; Patthy L
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
    Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
    Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.